We invest in companies that leverage AI-native platforms and molecular design to speed discovery, enhance diagnosis, and optimize therapeutics.

Platforms optimizing molecular therapeutics through engineering

Computationally enabled platforms advancing discovery and diagnostics, making science more measurable and actionable

Software advancing research, diagnostics, therapeutics, and healthcare operations

Technologies reducing cost, enabling flexibility, and bringing treatments closer to patients